46Integrated efficacy and safety exposure response (ER) analysis of tivozanib (TIVO) for the treatment of renal cell cancer (RCC)
Bradley A. McGregor(Harvard University), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal), Alex Chehrazi‐Raffle(City of Hope), Pedro C. Barata(University Hospitals Seidman Cancer Center), Claudia Lebedinsky(European Institute of Oncology), Benjamin Garmezy(Sarah Cannon), Rana R. McKay(University of California San Diego), Edgar Braendle(AVEO Oncology (United States)), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Laurence Albigès(Université Paris-Saclay), Monette Cotreau(HealthPartners), Bo Jin, Philippe Barthélémy(Institut de Cancérologie Strasbourg), Hans J. Hammers(Southwestern Medical Center), Daniel Yick Chin Heng(University of Calgary), Sheik Emambux(Centre Hospitalier Universitaire de Poitiers), Katy Beckermann(Vanderbilt University Medical Center), Toni Choueri(Dana-Farber Cancer Institute)
Cited by 0
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k